Cempra announces positive results of intravenous solithromycin

Cempra announced results of its Phase 1 study of intravenous solithromycin in healthy subjects. The study demonstrated that IV solithromycin was well tolerated, showed a favorable pharmacokinetic profile and achieved relevant plasma concentrations.

Advertisement